Blog
Featured post
Truveta Data now includes more than 120 million de-identified patients
Truveta has also partnered with more than 100 organizations across life sciences, healthcare, public health, academic research organizations, and others to use regulatory-grade EHR data enabling scientifically rigorous research.
ISPE 2024: Exploring the impact of removing race as a diagnostic factor for chronic kidney disease: Time to potassium-lowering drugs
Authors: Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc,...
ISPE 2024: Real-world patterns in GLP-1 RA switching from 2018-2023 in the US
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue,...
Truveta moves up on GeekWire’s Top 200 startup list
Truveta was included in GeekWire’s latest list recognizing the top 200 startups in the Pacific Northwest. With this update of the GeekWire 200, Truveta moved up 14 spots to #38...
Advancing psoriasis research with regulatory-grade EHR data
Psoriasis is more than just a skin condition – it’s a chronic, systemic disease that affects over 8 million people in the United States, profoundly impacting their quality of...
Exploring medication switching trends from Humira to approved biosimilars
Authors: Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA,...
Improving ovarian cancer outcomes with EHR data
By the time most women with ovarian cancer are diagnosed, 70-80% are already at an advanced stage of the disease. Despite declining mortality rates over the past decade, the...
Scaling AI models for growth
In this blog I will discuss our approach to scaling our AI technologies across multiple dimensions while controlling development costs, operational costs, and assuring stability....
Truveta Research leads first study to explore GLP-1 reinitiation trends and factors
This study characterized discontinuation and reinitiation of GLP-1 medications for a large population of patients with overweight or obesity who started a GLP-1 medication...
Trends in testing and diagnosis of peripheral vascular disease in the US
The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first...